Mineralys completes enrollment for hypertension drug trial
RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...
Mineralys Therapeutics completes enrollment in Explore-CKD Phase 2 trial
Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...